
Allergy
-
In all patients, always inquire about any allergy and clearly document it in the chart. Re-evaluate this periodically.
-
Clarify the manifestations of a reaction in order to try to diagnose a true allergic reaction (e.g., do not misdiagnose viral rashes as antibiotic allergy, or medication intolerance as a true allergy).
-
In a patient reporting allergy (e.g., to food, to medications, environmental), ensure that the patient has the appropriate medication to control symptoms (e.g., antihistamines, bronchodilators, steroids, an EpiPen).
-
Prescribe an EpiPen to every patient who has a history of, or is at risk for, anaphylaxis.
-
Educate appropriate patients with allergies (e.g., to food, medications, insect stings) and their families about the symptoms of anaphylaxis and the self-administration of the EpiPen, and advise them to return for immediate reassessment and treatment if those symptoms develop or if the EpiPen has been used.
-
Advise patients with any known drug allergy or previous major allergic reaction to get a MedicAlert bracelet.
-
In a patient presenting with an anaphylactic reaction:
-
Recognize the symptoms and signs.
-
Treat immediately and aggressively.
-
Prevent a delayed hypersensitivity reaction through observation and adequate treatment (e.g., with steroids).
-
-
In patients with anaphylaxis of unclear etiology refer to an allergist for clarification of the cause.
-
In the particular case of a child with an anaphylactic reaction to food:
-
Prescribe an EpiPen for the house, car, school, and daycare.
-
Advise the family to educate the child, teachers, and caretakers about signs and symptoms of anaphylaxis, and about when and how to use the EpiPen.
-
-
In a patient with unexplained recurrent respiratory symptoms, include allergy (e.g., sick building syndrome, seasonal allergy) in the differential diagnosis.
Drug Reaction Classification
-
Type A - Adverse reaction
-
Type B - Hypersensitivity
-
Exaggerated sensitivity to known drug toxicity (eg. tinnitus with single dose of aspirin)
-
Idiosyncratic drug reaction (due to genetic differences, eg. hemolytic anemia in G6PD after primaquine)
-
Immunologic/Drug allergy
-
Type I - Immediate IgE (mast cells +/- basophils)
-
Within 30mins-1h
-
Urticarial rash, pruritus, flushing, angioedema, wheezing, GI symptoms, hypotension
-
Anaphylaxis is the most severe type of presentation
-
-
Type II - Delayed antibody (IgG) mediated cell destruction
-
Usually 5-8d after exposure
-
Hemolytic anemia, thrombocytopenia, neutropenia
-
-
Type III - Delayed IgG: drug immune complex deposition and complex activation
-
Usually 1-2 weeks after exposure
-
May have a low complement, high ESR
-
Serum sickness - fever, urticarial/purpuric rash, arthralgia, acute glomerulonephritis (eg. antitoxin)
-
Vasculitis - palpable purpura/petechiae, often lower extremities (eg. penicillins, cephalosporins, sulfonamides, phenytoin, allopurinol)
-
Arthus reaction - localized skin inflammation, necrosis (post-vaccine)
-
-
Type IV - Delayed T-cell mediated
-
>48h, usually days-weeks after exposure (but <24h upon re-exposure)
-
SJS/TEN - fever, painful diffuse erythema, bullae, oral/mucosal erosions, necrosis and skin sloughing/epidermal detachment (eg. allopurinol, lamotrigine, anticonvulsants, sulfonamides, COX2i NSAIDs, mycoplasma pneumoniae)
-
DRESS - fever, skin eruption, eosphinophilia (or atypical lymphocytosis), lymphadenopathy, organ involvement (anticonvulsants, sulfonamides)
-
Other: Contact dermatitis, maculopapular eruptions
-
-
-
Anaphylaxis Diagnosis
If one of the following
-
Acute onset of illnesss (minutes to several hours) with involvement of skin, mucosal tissue or both (eg, generalized hives, pruritus or flushing, or swollen lips-tongue-uvula) and at least one of the following:
-
Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF or hypoxemia)
-
Reduced BP or associated symptoms of end-organ dysfunction (eg, hypotonia [collapse], syncope or incontinence)
-
-
Two or more of the following that occur rapidly after exposure to a likely allergen for that patient (minutes to several hours):
-
Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush or swollen lips-tongue-uvula)
-
Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF or hypoxemia)
-
Reduced BP or associated symptoms of end-organ dysfunction (eg, hypotonia [collapse], syncope or incontinence)
-
Persistent gastrointestinal symptoms (eg, crampy abdominal pain or vomiting)
-
-
Reduced BP after exposure to a known allergen for that patient (minutes to hours)
-
Low BP for children defined as <70mmHg + [2 x age] up to 10yo
-
History
-
Anaphylaxis symptoms
-
General/CNS - Lethargy, somnolence, altered LOC, syncope
-
Upper airway - Hoarseness, stridor, oropharyngeal/laryngeal/uvular edema, lip/tongue swelling, obstruction
-
Lower airway - Cough, dyspnea, tachypnea
-
Skin - Flushing, erythema, pruritus, urticaria, angioedema, maculopapular rash
-
CVS - Tachycardia, hypotension, arrhythmia, acute coronary syndrome
-
GI - N/V/D, abdominal pain
-
-
Trigger
-
Food (peanuts, tree nuts, fish, milk, eggs, shellfish [shrimp, lobster, crab, scallops, oysters])
-
Hymenoptera (bee/wasp) stings
-
Medications
-
-
Previous allergies and allergical reaction
Physical Examination
-
ABC, Vitals (Hypotension, tachycardia)
-
CVS
-
Resp
-
Abdominal exam
-
Skin
DDx
-
Respiratory
-
Asthma
-
Foreign body aspiration
-
-
Cardiovascular
-
Pulmonary embolism
-
Acute coronary syndrome
-
-
Shock
-
Mast cell disorder
Management of Anaphylaxis
-
ABC, vitals, monitors, IV x2, oxygen
-
Airway (intubation if impending airway obstruction)
-
-
Epinephrine 0.5mg IM mid-antero-lateral thigh q5mins x3 doses (Caution if bolus via IV)
-
0.01mg/kg (0.01mL/kg of 1:1000 = 1mg/1mL) in children up to 0.3mg (eg. 30kg child should receive 0.3mg IM)
-
Infusion of epinephrine 0.1mcg/kg/min IV titrate to vitals (usually need 5-15mcg/min)
-
If on beta-blockers and poor response to epinephrine, consider glucagon 1-5mg IV over 5 minutes
-
-
Aggressive fluid resuscitation
-
Lie down, elevate legs
-
>1-2L (20mL/kg) NS IV bolus, repeat PRN
-
-
Salbutamol for bronchospasm 2.5-5mg in 3mL saline via nebulizer (or 5-10 puffs MDI with spacer), repeat PRN
-
Adjunctive
-
Antihistamine
-
H1 antagonist, eg. Diphenhydramine (1mg/kg/dose) 25-50mg PO/IM/IV q4-6h PRN
-
H2 antagonist, eg. Ranitidine 150mg IV, Famotidine 20mg IV
-
-
Glucocorticoids (Note: no evidence in decreasing return ER visits or biphasic reactions)
-
Methylprednisolone 1-2mg/kg/d (max 125mg IV)
-
Prednisone 1mg/kg PO (max 50mg PO)
-
-
-
Observation period for biphasic reactions (incidence of 20%, can occur up to 6 days)
-
Although most guidelines suggest 4, 6 or 24h of observation there is no data to suggest this improves outcomes
-
Consider discharge in patients with prompt and complete symptom resolution
-
Consider observation if
-
Risk factors (Previous biphasic, asthma)
-
Severe features (Refractory hypotension, laryngeal edema, and respiratory compromise)
-
Delayed or suboptimal treatment
-
-
-
-
If not improved with anti-histamine treatment consider bradykinin-mediated angioedema
-
Treat with Tranexamic acid 1g IV, Fresh frozen plasma (2 units), C1-inhibitor concentrate
-
Investigations
-
Serum tryptase levels taken 15-180mins after symptom onset may support diagnosis
-
Compare to baseline tryptase improves accuracy
-
-
If no cause identified, rule out mast cell disorder
Discharge
-
Education to patient, friends/family
-
Risk of biphasic reaction
-
Avoidance of triggers
-
Anaphylaxis emergency plan (self-administered epinephrine, call 9-1-1)
-
Printed and explain information about signs/symptoms of anaphylaxis and treatment
-
Teaching and practice on how to administer the self-injectable epinephrine
-
-
-
Prescribe minimum two epinephrine auto-injector to be carried on patient at all times
-
EpiPenJR or TwinjectJR <25kg
-
EpiPen or Twinject>25kg
-
-
MedicAlert bracelet
-
Allergy referral if needed to clarify trigger
References:
-
ASCIA 2017. https://www.allergy.org.au/health-professionals/papers/acute-management-of-anaphylaxis-guidelines
-
WAOJ 2015. https://waojournal.biomedcentral.com/articles/10.1186/s40413-015-0080-1
-
CPS 2011. http://www.cps.ca/en/documents/position/emergency-treatment-anaphylaxis
-
CMAJ 2003. http://www.cmaj.ca/content/169/4/307.full